GTM Container Code

This site requires JavaScript and cookies to be enabled.

Empower Your Parkinson’s Patients With APOKYN®

Give patients a treatment to help control their acute OFF episodes.1


Icon: Reliable

Reversed 95% of OFF episodes (primary endpoint).2

Icon: Robust

Substantial improvements in UPDRS III scores.3

- 19.9 Points at 10 minutes (secondary endpoint)3

- 24.2 Points at 20 minutes (primary endpoint)3

Icon: Rapid

Significantly improved motor function in as early as:

- 10 minutes (secondary endpoint)3

- 20 minutes (primary endpoint)3

Study design: A randomized, double-blind, placebo-controlled trial in 29 patients with advanced PD for Parkinsonian OFF-state events. Patients were randomized to receive titrated doses of APOKYN or matched placebo. Primary efficacy endpoint was the change in Unified Parkinson’s Disease Rating Scale (UPDRS) motor score 20 minutes post-injection in the inpatient phase. In the outpatient phase, % of injections aborting OFF-state events was the primary efficacy endpoint. Secondary efficacy endpoints included change in UPDRS motor scores at 10 and 90 minutes and change in Webster Step-Seconds Test (WSST) score.1,2

Study design: A prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in 62 patients with advanced PD who experienced OFF episodes despite optimal oral therapy. Patients used APOKYN as acute, intermittent therapy for 14.5 months on average before the study. Patients were randomized to receive a single dose of APOKYN or placebo at the typically effective dose, or 0.2 mL higher than that dose, in response to an OFF episode that occurred more than 1 hour after a typical morning dose of oral PD therapy. Mean dose for the APOKYN-treated group was 0.42 mL.1,3

Circle of CareTM

The Circle of Care is a unique program designed to assist patients and their care partners in the use of APOKYN.

Circle of Care Program